Contact this trialFirst, we need to learn more about you.
Apitegromab for Spinal Muscular Atrophy
Recruiting1 awardPhase 3
Salt Lake City, Utah
This trial is testing a new drug, apitegromab, as an adjunctive therapy to nusinersen or risdiplam, for patients with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA). The trial will confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.